TTY Biopharm Company Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	2,798	2,521	2,773	2,621	2,357	2,222
Short-Term Investments	509.6	467.74	309.02	195.54	326.86	372.65
Cash & Short-Term Investments	3,307	2,989	3,082	2,817	2,684	2,595
Cash Growth	2.25%	-3.02%	9.41%	4.93%	3.44%	1.12%
Accounts Receivable	1,352	1,518	1,354	1,344	1,227	1,138
Other Receivables	33.4	36.46	23.18	28.81	29.68	13.62
Receivables	1,385	1,554	1,377	1,373	1,257	1,151
Inventory	1,406	1,389	1,270	1,096	1,039	955.01
Prepaid Expenses	58.74	-	-	79.02	49.89	46.96
Other Current Assets	29.57	76.88	64.58	6.36	5.37	1.15
Total Current Assets	6,187	6,009	5,793	5,370	5,035	4,749
Property, Plant & Equipment	2,176	2,199	2,246	2,287	2,433	2,519
Long-Term Investments	2,244	2,205	1,940	1,578	1,496	1,432
Goodwill	247.9	247.9	247.9	-	-	-
Other Intangible Assets	344.54	177.27	123.44	164.01	250.75	124.9
Long-Term Deferred Tax Assets	65.8	65.8	58.52	48.71	47.1	63.72
Other Long-Term Assets	410.39	444.8	453.25	426.94	337.89	407.19
Total Assets	11,676	11,348	10,863	9,875	9,601	9,296
Accounts Payable	298.96	270.78	326.16	294.66	289.4	187.27
Short-Term Debt	500	700	1,200	1,450	1,370	1,711
Current Portion of Long-Term Debt	500	500	400	-	418.85	407.91
Current Portion of Leases	8.72	8.35	0.93	5.86	3.92	7.62
Current Income Taxes Payable	434.15	323.68	228.8	156.97	149.52	150.39
Current Unearned Revenue	31.49	53.7	34.34	14.23	33.13	39.77
Other Current Liabilities	1,848	783.33	672.18	662.02	652.62	547.55
Total Current Liabilities	3,621	2,640	2,862	2,584	2,917	3,052
Long-Term Debt	-	-	100	400	9.6	4.15
Long-Term Leases	6.42	7.4	10.2	3.05	3.04	14.16
Pension & Post-Retirement Benefits	16.9	17.01	17.54	27.4	40.81	52.6
Long-Term Deferred Tax Liabilities	363.19	363.19	359.24	318.75	305.44	260.52
Other Long-Term Liabilities	269.32	269.3	2.44	35.83	91.03	146.23
Total Liabilities	4,277	3,297	3,352	3,369	3,367	3,529
Common Stock	2,487	2,487	2,487	2,487	2,487	2,487
Additional Paid-In Capital	317.56	317.56	317.04	316.62	312.18	311.88
Retained Earnings	3,751	4,427	3,888	3,182	2,925	2,568
Comprehensive Income & Other	12.98	7.18	58.69	-43.79	-64.78	-198.07
Total Common Equity	6,568	7,238	6,750	5,941	5,658	5,168
Minority Interest	830.33	812.93	760.49	564.8	574.86	599.38
Shareholders' Equity	7,399	8,051	7,511	6,506	6,233	5,767
Total Liabilities & Equity	11,676	11,348	10,863	9,875	9,601	9,296
Total Debt	1,015	1,216	1,711	1,859	1,805	2,145
Net Cash (Debt)	2,292	1,773	1,371	957.65	878.78	450
Net Cash Growth	33.05%	29.36%	43.11%	8.97%	95.28%	6.52%
Net Cash Per Share	9.20	7.11	5.50	3.84	3.53	1.81
Filing Date Shares Outstanding	248.65	248.65	248.65	248.65	248.65	248.65
Total Common Shares Outstanding	248.65	248.65	248.65	248.65	248.65	248.65
Working Capital	2,566	3,369	2,931	2,787	2,118	1,698
Book Value Per Share	26.42	29.11	27.15	23.89	22.76	20.78
Tangible Book Value	5,976	6,813	6,379	5,777	5,408	5,043
Tangible Book Value Per Share	24.03	27.40	25.65	23.23	21.75	20.28
Land	-	902.9	902.9	902.9	902.9	902.9
Buildings	-	1,495	1,479	1,461	1,432	1,420
Machinery	-	1,443	1,446	1,432	1,418	1,359
Construction In Progress	-	71.53	0.59	8.95	77.09	95